Heavy menstrual bleeding is the most common symptom in females with bleeding disorders, and it can have a significant impact on a person's quality of life. The purpose of this study is to learn more about a drug called tranexamic acid (TA), otherwise known as Lysteda, and to determine whether or not this drug can decrease menstrual blood loss in young women to increase their quality of life.
TA is a hormone-free fmedicine that has been approved by the FDA for use in patients who are at least 18 years of age, but not for younger patients.
Females ages 10-19 years old who experience heavy menstrual bleeding and are non-smokers are eligible for this study.
Participation in this study will last for about six (6) months. There are two required study visits at which a physical exam will be completed and blood will be drawn, and there are four telephone calls.
All patients will take tranexamic acid (TA) during their menses for three (3) months. The study will also include surveys each month to record the heaviness of menstrual bleeding and how it affects everyday life (school, extracurrical activities, etc.)
Possible benefits to the participant may be an improvement in quality of life and a decrease in menstrual blood loss. Additionally, for their time and inconvenience, participants will receive gift cards after completing several study milestones.
If you want to learn more or are interested in participating in this study, please contact either of the following two individuals:
Heidi Ziegler, RN
Phone: (614) 722-3883
Sarah O'Brien, MD
Phone: (614) 722-6230